ObjectiveTo observe the clinical effects of rabeprazole combined with mosapride in the treatment of patients with reflux esophagitis and the occurrence of adverse reactions. MethodsA total of 172 patients with reflux esophagitis who were treated in our hospital from May 2018 to August 2020 were selected as the research objects. According to the random number method, the patients were divided into control group and observation group, with 86 cases in each group. The control group was treated with rabeprazole, and the observation group was treated with rabeprazole combined with mosapride, for an 8-week treatment course. The clinical efficacy, gastroscopic efficacy, clinical symptom disappearance time and adverse reactions of the two groups were compared. ResultsAfter 8 weeks of treatment, the total effective rate of clinical treatment in the observation group (87.21%) was significantly higher than that in the control group (67.44%), with a statistically significant difference (P＜0.05). The total effective rate of gastroscopic treatment in the observation group (91.86%) was significantly higher than that in the control group (74.42%), with a statistically significant difference (P＜0.05). The disappearance time of acid regurgitation, retrosternal pain and retrosternal burning sensation of patients in the observation group were significantly shorter than those of the control group, with statistically significant differences (P＜0.05). During the treatment, the occurrence of adverse reactions in the observation group (12.79%) was slightly higher than that in the control group (11.63%), but the difference was not statistically significant (P＞0.05). ConclusionThe application of rabeprazole combined with mosapride in reflux esophagitis achieved significant clinical efficacy. It can effectively improve the symptoms and clinical efficacy of patients, and has good therapeutic safety.

无